Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-L1 t-haNK + N-803 + cetuximab
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination immunotherapy regimen is being investigated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). It consists of three distinct agents: **PD-L1 t-haNK**, an allogeneic natural killer (NK) cell line engineered to express a PD-L1-targeting chimeric antigen receptor (CAR) and a high-affinity CD16 receptor; **N-803 (Anktiva)**, an IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor alpha/IgG1 Fc fusion protein; and **cetuximab (Erbitux)**, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The regimen is designed to overcome resistance to prior checkpoint inhibitors by stimulating NK and CD8+ T cell activity via N-803, while PD-L1 t-haNK and cetuximab provide targeted tumor cell killing through CAR-mediated activity and antibody-dependent cellular cytotoxicity (ADCC).
- Other names
- nogapendekin alfa inbakicept-pmlnPD-L1 t-haNKPD-L-1 t-haNKPD-L 1 t-haNKcetuximab
02
Targets
EGFR (Epidermal growth factor receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PD-L1 t-haNK + N-803 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-L1 t-haNK + N-803 + cetuximab.